MedTrace Logo

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

NCT01362348 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-09-21

Study results available
· View outcomes & findings →

Summary

The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.

Conditions

  • Macular Degeneration

Interventions

DRUG

pazopanib eye drops

10 mg/mL (1 drop) four times daily

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-07
Primary Completion
2012-04-16
Completion
2012-04-16

Countries

  • United States
  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01362348 on ClinicalTrials.gov